Peptidomimetic inhibitors of cathepsin and plasmepsins I and II

Type
Compound(s)

The invention relates to the design and synthesis of linear and cyclic inhibitors of cathepsin D and plasmepsins I and II. The present invention also relates to the uses of these inhibitors for inhibiting invasion and metastasis of cancerous cells. It also covers the use of cathepsin D and plasmepsin I and II inhibitors for the prevention and treatment of Alzheimer's disease and malaria.
NIH Internal Reference no E-221-1994/0-US-01; US Patent Application no 08/603,737; E-221-1994/0-AU-03; AU Patent Application no 21368/97;E-221-1994/0-CA-04; CA Patent Application no 2246758; E-221-1994/0-EP-05; EP Patent Application no 97906763.4; E-221-1994/0-JP-06; JP Patent Application no 9-529609; The invention relates to the design and synthesis of linear and cyclic inhibitors of cathepsin D and plasmepsins I and II. The present invention also relates to the uses of these inhibitors for inhibiting invasion and metastasis of cancerous cells. It also covers the use of cathepsin D and plasmepsin I and II inhibitors for the prevention and treatment of Alzheimer's disease and malaria.

Disease
Malaria
Research areas
Basic research
Drug
Condition of use

n/a

IP information

Abandoned Patent Reference Number(s): E-221-1994/0-AU-03; US Patent no 5,849,691; NIH Internal Reference no E-221-1994/0-US-01; E-221-1994/0-CA-04; CA Patent no 2246758; AU Patent no 726206